Literature DB >> 88539

Oncofetal antigen: a tumor-associated fetal antigen immunogenic in man.

R F Irie, A E Giuliano, D L Morton.   

Abstract

Oncofetal antigen (OFA) has been defined with the use of human natural antibodies as a membrane antigen of human cancer cells that cross-reacts with human fetal brain tissues. The immunogen that elicits the antibody is unknown. The present study was undertaken to examine the immunogenicity of the OFA found on tumor cells. Postoperative melanoma patients were immunized with OFA-positive melanoma cells. Anti-OFA reactivities in the immunized sera were titrated by the immune adherence assay with the use of a known OFA-positive cultured melanoma cell line, M14, as target cell. Alloantibodies were excluded by absorption with lymphoblastoid cells autologous to M14. Anti-OFA antibody then was identified by absorption with fetal brain. In 6 months of immunization, 19 of 23 patients produced increased anti-OFA antibodies. The peak titers ranged from 1:16 to 1:2,048. Sera from 18 patients who were not immunized also were tested for 6 months postoperatively, and none had significant increases in antibody titers. The increase of anti-OFA antibody titer in response to the immunization with OFA-positive tumor cells suggests the immunogenic capability of tumor-related OFA in man.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 88539

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  10 in total

1.  Human antibody to OFA-I, a tumor antigen, produced in vitro by Epstein-Barr virus-transformed human B-lymphoid cell lines.

Authors:  R F Irie; L L Sze; R E Saxton
Journal:  Proc Natl Acad Sci U S A       Date:  1982-09       Impact factor: 11.205

2.  Identification of a human neuroectodermal tumor antigen (OFA-I-2) as ganglioside GD2.

Authors:  L D Cahan; R F Irie; R Singh; A Cassidenti; J C Paulson
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

3.  Ganglioside GM2 as a human tumor antigen (OFA-I-1).

Authors:  T Tai; J C Paulson; L D Cahan; R F Irie
Journal:  Proc Natl Acad Sci U S A       Date:  1983-09       Impact factor: 11.205

4.  Reaction of the leukocytes of melanoma patients and control donors, including pregnant women, with melanoma- and fetus-derived materials.

Authors:  A J Cochran; G Todd; D M Hart; L J Morrison; R M MacKie
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

5.  Phase II study of vaccinia melanoma cell lysates (VMCL) as adjuvant to surgical treatment of stage II melanoma. II. Effects on cell mediated cytotoxicity and leucocyte dependent antibody activity: immunological effects of VMCL in melanoma patients.

Authors:  P Hersey; A Edwards; G D'Alessandro; M MacDonald
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

6.  Induction of antibodies to a tumor-associated antigen by immunization with a whole melanoma cell vaccine.

Authors:  D M Euhus; R K Gupta; D L Morton
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

7.  Oncofoetal antigen I: a target for immune cytolysis of human cancer.

Authors:  N Sidell; R F Irie; D L Morton
Journal:  Br J Cancer       Date:  1979-12       Impact factor: 7.640

8.  In vitro production of human antibody to a tumour-associated foetal antigen.

Authors:  R F Irie; P C Jones; D L Morton; N Sidell
Journal:  Br J Cancer       Date:  1981-08       Impact factor: 7.640

Review 9.  Cancer vaccines.

Authors:  Lisa H Butterfield
Journal:  BMJ       Date:  2015-04-22

Review 10.  The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans.

Authors:  Benjamin A H Smith; Carolyn R Bertozzi
Journal:  Nat Rev Drug Discov       Date:  2021-01-18       Impact factor: 84.694

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.